Related references
Note: Only part of the references are listed.Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002
Lisa J. Herrinton et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Murat Toruner et al.
GASTROENTEROLOGY (2008)
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy:: A review of 84 cases
Nirmal Kaur et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Serious adverse events with infliximab: Analysis of spontaneously reported adverse events
Richard A. Hansen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Gastroenterology 2 - Inflammatory bowel disease: clinical aspects and established and evolving therapies
Daniel C. Baumgart et al.
LANCET (2007)
Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings
Lisa J. Herrinton et al.
INFLAMMATORY BOWEL DISEASES (2007)
Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugs
J. R. Curtis et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease
Gauree Gupta et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
GR Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Crohn's disease:: increased mortality 10 years after diagnosis in a Europe-wide population based cohort
FL Wolters et al.
GUT (2006)
Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease
A Agrawal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2005)
Infections in patients with rheumatoid arthritis treated with biologic agents
J Listing et al.
ARTHRITIS AND RHEUMATISM (2005)
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
A Kandiel et al.
GUT (2005)
Granulomatous infectious diseases associated with tumor necrosis factor antagonists
RS Wallis et al.
CLINICAL INFECTIOUS DISEASES (2004)
Tumor necrosis factor antagonist therapy and lymphoma development - Twenty-six cases reported to the Food and Drug Administration
SL Brown et al.
ARTHRITIS AND RHEUMATISM (2002)
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
JH Lee et al.
ARTHRITIS AND RHEUMATISM (2002)
Long-term evolution of disease behavior of Crohn's disease
J Cosnes et al.
INFLAMMATORY BOWEL DISEASES (2002)
Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine
GA Dayharsh et al.
GASTROENTEROLOGY (2002)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
